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Cumulative Discontinuous Neutropenia Predicts 
Risk of Invasive Asper~illosis both during and 
after Resolution of Neutropenia in Patients with 
Hematologic Malignancy 
R.C. Watker*, N. Issa, T.L. Hoskin, J.L. St Sauver, 
C.D. Schteck. Mayo Clinic Collese of Medicine, 
Rochester, MN, USA 
Problem: Cumutative discontinuous neutropenia 
(CDN) denotes the totat number of days of neu- 
tropenia that can accrue across muttipte episodes 
of chemotherapy-induced neutropenia - and may 
predict risk for infection. Determining CDN is diffi- 
cult because patients do not have blood tests every 
day. 
Method: We developed software that extracts 
existing neutrophil counts and then derives, by 
interpolation, a neutrophil count for every day 
in between. We then analyzed all cases of 
leukemia (861) and lymphoma (1418) at Mayo CUnic 
from 1990 to 2000. For each case, a date-specific 
flew was built that indicated whether or not the 
patient was neutropenic (absolute neutrophil count 
<500) on each of the 365 clays fottowing the pa- 
tient's first treatment for their hematologic ma- 
Ugnancy. We then identified the date of first di- 
agnosis of Invasive Aspersillosis (IA, definite and 
probable, per estabUshed guideUnes) among all 
of these patients, by cross-referencing our co- 
hort with a previousty assembted database of at[ 
IA infections, and atso with infection contro[ data, 
autopsy reports and microbiotogy data. One each 
of the day-numbers (1-365) on which a case of 
IA occurred, we determined the median and range 
of CDN days that had accrued among at[ the pa- 
tients who had survived up through that same day- 
number. 
Results: With [eukemia, 23/27 (85.2%) of IA cases 
had a CDN day-count, at the time of their IA diagno- 
sis, that was above the median for at[ [eukemia pa- 
tients fottowed through that same time, (p-vatue = 
0.0003). There were significantty more CDN days 
for IA cases (compared to non-lA cases), whether 
the IA was diagnosed within a neutropenic episode, 
(11/12, 91.7%, p=0.004) or after a neutropenic 
episode (12/15, 80%, p=0.02). In [ymphoma, 4 of 
12 IA cases (33%) had a CDN value at the time 
of IA diagnosis that was above the 95 percentite 
for at[ [ymphoma patients fottowed through that 
time (p< 0.0001). The ratio of CDN days to tota[ 
surviva[ days among IA patients was twice as high 
as non-lA cases during the first 42 days (0.6 versus 
0.3) and from days 43 to 120 (0.34 versus 0.18), 
and nearty three times as high during days 121 to 
365 (0.27 versus 0.1 ). 
Conclusion: Future, muttivariate studies that an- 
atyze risk factors for IA need to inctude CDN as 
a contributing variabte. CDN atso appears to affect 
the risk for IA even after resotution of neutropenia. 
